Tony Mok

1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
   2018/09/25 by Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna +20 · 50 citations
   Medicine · #Lung Cancer Research Studies #Peptidase Inhibition and Analysis #Cancer Immunotherapy and Biomarkers
2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
   2019/04/04 by Tony Mok, Tony S K Mok, Yi-Long Wu +283 · 3 citations
   Medicine · #Cancer Immunotherapy and Biomarkers #Lung Cancer Diagnosis and Treatment #Radiomics and Machine Learning in Medical Imaging
3. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
   2023/01/17 by L.E. Hendriks, Lizza Hendriks, K.M. Kerr +21 · 4 citations
   Medicine · #Lung Cancer Treatments and Mutations #Lung Cancer Diagnosis and Treatment #Cancer Immunotherapy and Biomarkers
4. De-novo and acquired resistance to immune checkpoint targeting
   2017/12/01 by Nicholas L Syn, Nicholas Syn, Michele W L Teng +5 · 1 citation
   Biochemistry, Genetics and Molecular Biology · Medicine · #CAR-T cell therapy research #Cancer Genomics and Diagnostics #Cancer Immunotherapy and Biomarkers